Donor-derived Cell-free DNA for Early Diagnosis of Antibody-mediated Rejection (cfDNA-DSA)
Donor-derived Cell-free DNA for Early Diagnosis of Antibody-mediated Rejection in Kidney Transplant Recipient with Donor-specific Antibodies
Sponsor: Charite University, Berlin, Germany
A NA clinical study on Antibody-mediated Rejection and Kidney Transplant Failure, this trial is completed. The trial is conducted by Charite University, Berlin, Germany and has accumulated 11 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Feb 2025 — Present [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Sep 2024 — Feb 2025 [monthly]
Active Not Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting NA
-
Feb 2024 — Jul 2024 [monthly]
Active Not Recruiting NA
-
Oct 2023 — Feb 2024 [monthly]
Active Not Recruiting NA
▶ Show 6 earlier versions
-
Aug 2023 — Oct 2023 [monthly]
Active Not Recruiting NA
-
Sep 2022 — Aug 2023 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jul 2022 — Sep 2022 [monthly]
Recruiting NA
-
Mar 2022 — Jul 2022 [monthly]
Recruiting NA
-
Sep 2021 — Mar 2022 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jun 2021 — Sep 2021 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Charite University, Berlin, Germany
For direct contact, visit the study record on ClinicalTrials.gov .